{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:55:11Z","timestamp":1793843711524,"version":"4.6.1"},"reference-count":93,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009002","name":"Ministry of Education and Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The World Health Organization, in response to the growing burden of fungal disease, established a process to develop a fungal priority pathogens list (FPPL). This systematic review aimed to evaluate the epidemiology and impact of invasive fungal disease due to Mucorales. PubMed and Web of Science were searched to identify studies published between January 1, 2011 and February 23, 2021. Studies reporting on mortality, inpatient care, complications and sequelae, antifungal susceptibility, risk factors, preventability, annual incidence, global distribution, and emergence during the study time frames were selected. Overall, 24 studies were included. Mortality rates of up to 80% were reported. Antifungal susceptibility varied across agents and species, with the minimum inhibitory concentrations lowest for amphotericin B and posaconazole. Diabetes mellitus was a common risk factor, detected in 65%\u201385% of patients with mucormycosis, particularly in those with rhino-orbital disease (86.9%). Break-through infection was detected in 13.6%\u2013100% on azole or echinocandin antifungal prophylaxis. The reported prevalence rates were variable, with some studies reporting stable rates in the USA of 0.094\u20130.117\/10\u2009000 discharges between 2011 and 2014, whereas others reported an increase in Iran from 16.8% to 24% between 2011 and 2015. Carefully designed global surveillance studies, linking laboratory and clinical data, are required to develop clinical breakpoints to guide antifungal therapy and determine accurate estimates of complications and sequelae, annual incidence, trends, and global distribution. These data will provide robust estimates of disease burden to refine interventions and better inform future FPPL.<\/jats:p>","DOI":"10.1093\/mmy\/myad130","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T20:10:23Z","timestamp":1719519023000},"source":"Crossref","is-referenced-by-count":22,"title":["Mucorales: A systematic review to inform the World Health Organization priority list of fungal pathogens"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9970-9575","authenticated-orcid":false,"given":"C Orla","family":"Morrissey","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Alfred Health and Monash University , Melbourne, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-5036","authenticated-orcid":false,"given":"Hannah Yejin","family":"Kim","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute (Sydney ID), The University of Sydney , Camperdown, New South Wales , Australia"},{"name":"Faculty of Medicine and Health, School of Pharmacy, The University of Sydney , Camperdown, New South Wales , Australia"},{"name":"Department of Pharmacy, Westmead Hospital , Westmead, New South Wales , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1607-0698","authenticated-orcid":false,"given":"Katherine","family":"Garnham","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Microbiology, Gold Coast University Hospital , Southport, Queensland , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0631-2975","authenticated-orcid":false,"given":"Aiken","family":"Dao","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute (Sydney ID), The University of Sydney , Camperdown, New South Wales , Australia"},{"name":"Department of Infectious Diseases, Sydney Medical School, Faculty of Medicine and Health, University of Sydney , Camperdown, New South Wales , Australia"},{"name":"Orthopaedic Research and Biotechnology Unit, Children\u2019s Hospital at Westmead , Westmead, New South Wales , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1555-3807","authenticated-orcid":false,"given":"Arunaloke","family":"Chakrabarti","sequence":"additional","affiliation":[{"name":"Doodhadhari Burfani Hospital and Research Institute , Haridwar , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0019-8638","authenticated-orcid":false,"given":"John R","family":"Perfect","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Health, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-4405","authenticated-orcid":false,"given":"Ana","family":"Alastruey-Izquierdo","sequence":"additional","affiliation":[{"name":"Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III , Majadahonda, Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3619-4348","authenticated-orcid":false,"given":"Thomas S","family":"Harrison","sequence":"additional","affiliation":[{"name":"Institute for Infection and Immunity, and Clinical Academic Group in Infection and Immunity, St. George\u2019s, University of London, and St. George's University Hospitals NHS Foundation Trust , London , United Kingdom"},{"name":"MRC Centre for Medical Mycology, University of Exeter , Exeter , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4515-8517","authenticated-orcid":false,"given":"Felix","family":"Bongomin","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu University , Gulu , Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Galas","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Special Program, Communicable Diseases and Environmental Determinants of Health, Pan American Health Organization , Washington, District of Columbia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siswanto","family":"Siswanto","sequence":"additional","affiliation":[{"name":"World Health Organization, South-East Asia Region Office , New Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Argaw","family":"Dagne","sequence":"additional","affiliation":[{"name":"Department of Control of Neglected Tropical Diseases, World Health Organization , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Roitberg","sequence":"additional","affiliation":[{"name":"Department of Noncommunicable Diseases, World Health Organization , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2496-6048","authenticated-orcid":false,"given":"Valeria","family":"Gigante","sequence":"additional","affiliation":[{"name":"AMR Division, World Health Organization , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2358-0522","authenticated-orcid":false,"given":"Hatim","family":"Sati","sequence":"additional","affiliation":[{"name":"AMR Division, World Health Organization , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Jan-Willem","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute (Sydney ID), The University of Sydney , Camperdown, New South Wales , Australia"},{"name":"Faculty of Medicine and Health, School of Pharmacy, The University of Sydney , Camperdown, New South Wales , Australia"},{"name":"Department of Pharmacy, Westmead Hospital , Westmead, New South Wales , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1978-1559","authenticated-orcid":false,"given":"Justin","family":"Beardsley","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute (Sydney ID), The University of Sydney , Camperdown, New South Wales , Australia"},{"name":"Department of Pharmacy, Westmead Hospital , Westmead, New South Wales , Australia"},{"name":"Westmead Institute for Medical Research , Westmead, New South Wales , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"2024062717013111900_bib1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/jof5010026","article-title":"Global epidemiology of mucormycosis","volume":"5","author":"Prakash","year":"2019","journal-title":"J Fungi"},{"key":"2024062717013111900_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.mycres.2007.03.004","article-title":"A higher-level phylogenetic classification of the Fungi","volume":"111","author":"Hibbett","year":"2007","journal-title":"Mycol Res"},{"issue":"Suppl 1","key":"2024062717013111900_bib3","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1093\/cid\/cir864","article-title":"Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives","volume":"54","author":"Kwon-Chung","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024062717013111900_bib4","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2024062717013111900_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/mmy\/myx017","article-title":"Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomes of reported cases","volume":"56","author":"Corzo-Le\u00f3n","year":"2018","journal-title":"Med Mycol"},{"key":"2024062717013111900_bib6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/mmy\/myy060","article-title":"A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment","volume":"57","author":"Prakash","year":"2019","journal-title":"Med Mycol"},{"issue":"Suppl 5","key":"2024062717013111900_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1469-0691.2009.02978.x","article-title":"Incidence of zygomycosis in transplant recipients","volume":"15","author":"Cuenca-Estrella","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"2024062717013111900_bib8","first-page":"2349","article-title":"Multicenter epidemiologic study of Coronavirus disease-associated mucormycosis, India","volume-title":"Emerg Infect Dis","author":"Patel","year":"2021"},{"key":"2024062717013111900_bib9","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","article-title":"Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007","volume":"17","author":"Skiada","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2024062717013111900_bib10","doi-asserted-by":"crossref","first-page":"E396","DOI":"10.1111\/j.1469-0691.2012.03908.x","article-title":"Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003\u20132008)","volume":"18","author":"Xhaard","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2024062717013111900_bib11","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1056\/NEJMoa1204781","article-title":"Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011","volume":"367","author":"Neblett\u00a0Fanfair","year":"2012","journal-title":"N Engl J Med"},{"key":"2024062717013111900_bib12","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/bjs.1800780819","article-title":"Gastrointestinal mucormycosis","volume":"78","author":"Thomson","year":"1991","journal-title":"Br J Surg"},{"key":"2024062717013111900_bib13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1055\/s-0029-1220775","article-title":"Zygomycosis in neonates: an uncommon but life-threatening infection","volume":"26","author":"Roilides","year":"2009","journal-title":"Am J Perinatol"},{"key":"2024062717013111900_bib14","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1186\/s12879-016-2023-z","article-title":"Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study","volume":"16","author":"Kontoyiannis","year":"2016","journal-title":"Bmc Infectious Diseases"},{"key":"2024062717013111900_bib15","article-title":"Filamentous fungal infections in a tertiary care setting: epidemiology and clinical outcome","volume":"7","author":"Van\u00a0Den\u00a0Nest","year":"2021","journal-title":"Journal of Fungi"},{"key":"2024062717013111900_bib16","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2024062717013111900_bib17","doi-asserted-by":"crossref","first-page":"D136","DOI":"10.1093\/nar\/gkr1178","article-title":"The NCBI Taxonomy database","volume":"40","author":"Federhen","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"2024062717013111900_bib18","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2024062717013111900_bib19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity","volume":"66","author":"Kim","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2024062717013111900_bib20","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/cid\/ciw563","article-title":"Detection of circulating Mucorales DNA in critically ill burn patients: preliminary report of a screening strategy for early diagnosis and treatment","volume":"63","author":"Legrand","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024062717013111900_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/myc.12897","article-title":"Mucormycosis-A clinicoepidemiological review of cases over 10 years","volume":"62","author":"Manesh","year":"2019","journal-title":"Mycoses"},{"key":"2024062717013111900_bib22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/myc.13038","article-title":"Characteristics and risk factors for mortality of invasive non-Aspergillus mould infections in patients with haematologic diseases: a single-centre 7-year cohort study","volume":"63","author":"Lee","year":"2020","journal-title":"Mycoses"},{"issue":"Suppl 3","key":"2024062717013111900_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/myc.12233","article-title":"Mucormycosis in children: a study of 22 cases in a Mexican hospital","volume":"57","author":"Bonifaz","year":"2014","journal-title":"Mycoses"},{"key":"2024062717013111900_bib24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jcrc.2019.02.005","article-title":"Epidemiology and clinical outcomes of invasive mould infections in Indian intensive care units (FISF study)","volume":"51","author":"Chakrabarti","year":"2019","journal-title":"J Crit Care"},{"key":"2024062717013111900_bib25","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jinf.2020.08.015","article-title":"Needles in a haystack: extremely rare invasive fungal infections reported in FungiScope(\u00ae)-Global Registry for emerging Fungal Infections","volume":"81","author":"Salmanton-Garc\u00eda","year":"2020","journal-title":"J Infect"},{"key":"2024062717013111900_bib26","doi-asserted-by":"crossref","first-page":"944.e9","DOI":"10.1016\/j.cmi.2019.11.021","article-title":"A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2024062717013111900_bib27","doi-asserted-by":"crossref","first-page":"e01230","DOI":"10.1128\/AAC.01230-18","article-title":"In vitro activity of isavuconazole against opportunistic fungal pathogens from two mycology reference laboratories","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062717013111900_bib28","doi-asserted-by":"crossref","first-page":"e00653","DOI":"10.1128\/AAC.00653-19","article-title":"A revised species concept for opportunistic mucor species reveals species-specific antifungal susceptibility profiles","volume":"63","author":"Wagner","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"2024062717013111900_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/myc.12234","article-title":"Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India","volume":"57","author":"Chowdhary","year":"2014","journal-title":"Mycoses"},{"key":"2024062717013111900_bib30","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1128\/AAC.00004-15","article-title":"Etest cannot be recommended for in vitro susceptibility testing of Mucorales","volume":"59","author":"Caramalho","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062717013111900_bib31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1186\/s12879-016-2005-1","article-title":"Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries","volume":"16","author":"Pana","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2024062717013111900_bib32","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/myc.13222","article-title":"Mucormycosis at a tertiary-care center in Mexico. A 35-year retrospective study of 214 cases","volume":"64","author":"Bonifaz","year":"2021","journal-title":"Mycoses"},{"key":"2024062717013111900_bib33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.mycmed.2018.02.014","article-title":"Mucormycosis in Iran: a six-year retrospective experience","volume":"28","author":"Dolatabadi","year":"2018","journal-title":"J Mycol Med"},{"key":"2024062717013111900_bib34","doi-asserted-by":"crossref","first-page":"810.e1","DOI":"10.1016\/j.cmi.2015.12.006","article-title":"Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF)","volume":"22","author":"Millon","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2024062717013111900_bib35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/ajd.13508","article-title":"Mucormycosis with cutaneous involvement. A retrospective study of 115 cases at a tertiary care hospital in Mexico","volume":"62","author":"Bonifaz","year":"2021","journal-title":"Australas J Dermatol"},{"key":"2024062717013111900_bib36","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2024062717013111900_bib37","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2024062717013111900_bib38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"2024062717013111900_bib39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/myc.13067","article-title":"Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: analysis of patients in the FungiScope(\u00ae) registry","volume":"63","author":"Jenks","year":"2020","journal-title":"Mycoses"},{"key":"2024062717013111900_bib40","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jhin.2019.09.020","article-title":"Invasive pulmonary aspergillosis: comparative analysis in cancer patients with underlying haematologic malignancies versus solid tumours","volume":"104","author":"Dib","year":"2020","journal-title":"J Hosp Infect"},{"key":"2024062717013111900_bib41","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.medmal.2012.10.001","article-title":"Rhino-orbito-cerebral mucormycosis: five cases","volume":"42","author":"Toumi","year":"2012","journal-title":"Med Mal Infect"},{"key":"2024062717013111900_bib42","doi-asserted-by":"crossref","first-page":"e63315","DOI":"10.1371\/journal.pone.0063315","article-title":"The global burden of visual difficulty in low, middle, and high income countries","volume":"8","author":"Freeman","year":"2013","journal-title":"PLoS One"},{"key":"2024062717013111900_bib43","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jobcr.2021.09.011","article-title":"A hidden community: facial disfigurement as a globally neglected human rights issue","volume":"11","author":"Swift","year":"2021","journal-title":"J Oral Biol Craniofac Res"},{"key":"2024062717013111900_bib44","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4103\/0975-5950.201361","article-title":"Naso-orbital fistula and socket reconstruction with radial artery forearm flap following orbital mucormycosis","volume":"7","author":"Bhatnagar","year":"2016","journal-title":"Natl J Maxillofac Surg"},{"key":"2024062717013111900_bib45","doi-asserted-by":"crossref","first-page":"101092","DOI":"10.1016\/j.ajoc.2021.101092","article-title":"Medical and surgical treatment of rhino-orbital-cerebral mucormycosis in a child with leukemia","volume":"22","author":"Levinsen","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2024062717013111900_bib46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.mmcr.2021.03.005","article-title":"Successful treatment of Rhizopus arrhizus rhino-orbital-cerebral mucormycosis with isavuconazole salvage therapy following extensive debridement","volume":"32","author":"Miller","year":"2021","journal-title":"Med Mycol Case Rep"},{"issue":"Suppl 7","key":"2024062717013111900_bib47","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/imj.15592","article-title":"Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than Aspergillus in the haematology\/oncology setting, 2021","volume":"51","author":"Bupha-Intr","year":"2021","journal-title":"Intern Med J"},{"key":"2024062717013111900_bib48","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/jac\/dkz344","article-title":"Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)","volume":"74","author":"Salmanton-Garc\u00eda","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024062717013111900_bib49","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1128\/AAC.04435-14","article-title":"Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales","volume":"59","author":"Espinel-Ingroff","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062717013111900_bib50","doi-asserted-by":"crossref","first-page":"e0123021","DOI":"10.1128\/JCM.01230-21","article-title":"Epidemiology and antifungal susceptibilities of mucoralean fungi in clinical samples from the United States","volume":"59","author":"Badali","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2024062717013111900_bib51","doi-asserted-by":"crossref","first-page":"115473","DOI":"10.1016\/j.diagmicrobio.2021.115473","article-title":"In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years","volume":"101","author":"Pfaller","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024062717013111900_bib52","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1128\/JCM.00318-16","article-title":"Role of antifungal susceptibility testing in non-Aspergillus invasive mold infections","volume":"54","author":"Lamoth","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2024062717013111900_bib53","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2024062717013111900_bib54","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.transproceed.2009.01.077","article-title":"Breakthrough rhinocerebral mucormycosis in a liver transplant patient receiving caspofungin","volume":"41","author":"Ramos","year":"2009","journal-title":"Transplant Proc"},{"key":"2024062717013111900_bib55","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cmi.2018.07.011","article-title":"The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports","volume":"25","author":"Jeong","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2024062717013111900_bib56","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1705614","article-title":"Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy","volume":"39","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"2024062717013111900_bib57","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1056\/NEJM200402263500923","article-title":"Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants","volume":"350","author":"Marty","year":"2004","journal-title":"N Engl J Med"},{"key":"2024062717013111900_bib58","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/422723","article-title":"Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis","volume":"39","author":"Siwek","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024062717013111900_bib59","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/423274","article-title":"Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole","volume":"39","author":"Imhof","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024062717013111900_bib60","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jac\/dkp430","article-title":"Forty-one recent cases of invasive zygomycosis from a global clinical registry","volume":"65","author":"Ruping","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2024062717013111900_bib61","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1086\/605445","article-title":"Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome","volume":"200","author":"Singh","year":"2009","journal-title":"J Infect Dis"},{"issue":"Suppl 5","key":"2024062717013111900_bib62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1469-0691.2009.02977.x","article-title":"The role of neutrophils in the development and outcome of zygomycosis in haematological patients","volume":"15","author":"Pagano","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"2024062717013111900_bib63","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1093\/jac\/dks189","article-title":"Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study","volume":"67","author":"Auberger","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2024062717013111900_bib64","first-page":"1610","article-title":"Breakthrough fungal infections in patients with leukemia receiving isavuconazole","volume":"67","author":"Rausch","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024062717013111900_bib65","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1086\/597615","article-title":"Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis","volume":"199","author":"Lamaris","year":"2009","journal-title":"J Infect Dis"},{"key":"2024062717013111900_bib66","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3201\/eid1509.090334","article-title":"Increasing incidence of zygomycosis (mucormycosis), France, 1997\u20132006","volume":"15","author":"Bitar","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"2024062717013111900_bib67","doi-asserted-by":"crossref","first-page":"e0092022","DOI":"10.1128\/mbio.00920-22","article-title":"Active surveillance program to increase awareness on invasive fungal diseases: the French RESSIF Network (2012 to 2018)","author":"Bretagne","year":"2022","journal-title":"mBio"},{"key":"2024062717013111900_bib68","first-page":"e23016","article-title":"Clinicopathological study of mucormycosis in COVID-19 patients: experience from a tertiary care center in South India","volume":"14","author":"Kandasamy","year":"2022","journal-title":"Cureus"},{"key":"2024062717013111900_bib69","doi-asserted-by":"crossref","first-page":"102146","DOI":"10.1016\/j.dsx.2021.05.019","article-title":"Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"2024062717013111900_bib70","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1016\/S2666-5247(20)30115-4","article-title":"Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study","volume":"1","author":"Hanley","year":"2020","journal-title":"Lancet Microbe"},{"key":"2024062717013111900_bib71","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/myc.13256","article-title":"The double-edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis","volume":"64","author":"Ahmadikia","year":"2021","journal-title":"Mycoses"},{"key":"2024062717013111900_bib72","doi-asserted-by":"crossref","first-page":"746","DOI":"10.5946\/ce.2020.180","article-title":"Rare and fatal gastrointestinal mucormycosis (zygomycosis) in a COVID-19 patient: a case report","volume":"53","author":"Monte\u00a0Junior","year":"2020","journal-title":"Clin Endosc"},{"key":"2024062717013111900_bib73","first-page":"e13163","article-title":"A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19","volume":"13","author":"Waizel-Haiat","year":"2021","journal-title":"Cureus"},{"key":"2024062717013111900_bib74","doi-asserted-by":"crossref","first-page":"101125","DOI":"10.1016\/j.mycmed.2021.101125","article-title":"Mucormycosis after coronavirus disease 2019 infection in a heart transplant recipient\u2014case report and review of literature","volume":"31","author":"Khatri","year":"2021","journal-title":"J Mycol Med"},{"key":"2024062717013111900_bib75","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s15010-020-01561-x","article-title":"A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis","volume":"49","author":"Pasero","year":"2021","journal-title":"Infection"},{"key":"2024062717013111900_bib76","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41368-020-0074-x","article-title":"High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa","volume":"12","author":"Xu","year":"2020","journal-title":"Int J Oral Sci"},{"key":"2024062717013111900_bib77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41574-020-00435-4","article-title":"COVID-19 and diabetes mellitus: from pathophysiology to clinical management","volume":"17","author":"Lim","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"2024062717013111900_bib78","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11046-020-00462-9","article-title":"Fungal co-infections associated with global COVID-19 pandemic: A clinical and diagnostic perspective from China","volume":"185","author":"Song","year":"2020","journal-title":"Mycopathologia"},{"key":"2024062717013111900_bib79","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/imm.12917","article-title":"Hypoxia and acidosis: immune suppressors and therapeutic targets","volume":"154","author":"Damgaci","year":"2018","journal-title":"Immunology"},{"key":"2024062717013111900_bib80","doi-asserted-by":"crossref","first-page":"101597","DOI":"10.1016\/j.bjid.2021.101597","article-title":"Is mucormycosis an inevitable complication of Covid-19 in India?","volume":"25","author":"Bhogireddy","year":"2021","journal-title":"Braz J Infect Dis"},{"key":"2024062717013111900_bib81","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41392-021-00819-6","article-title":"Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks","volume":"6","author":"Ruhl","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2024062717013111900_bib82","doi-asserted-by":"crossref","first-page":"10760296211042940","DOI":"10.1177\/10760296211042940","article-title":"Is it all about endothelial dysfunction and thrombosis formation? The secret of COVID-19","volume":"27","author":"Elyaspour","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"2024062717013111900_bib83","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"N Engl J Med"},{"key":"2024062717013111900_bib84","doi-asserted-by":"crossref","first-page":"e0009921","DOI":"10.1371\/journal.pntd.0009921","article-title":"COVID-19-associated mucormycosis: evidence-based critical review of an emerging infection burden during the pandemic's second wave in India","volume":"15","author":"Aranjani","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"2024062717013111900_bib85","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10384-021-00845-5","article-title":"Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations","volume":"65","author":"Bayram","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"2024062717013111900_bib86","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.4103\/ijo.IJO_340_22","article-title":"Analysis of COVID-19-associated rhino-orbital-cerebral mucormycosis patients in a tertiary care center in Northern India","volume":"70","author":"Yadav","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"2024062717013111900_bib87","first-page":"1","article-title":"Prosthetic rehabilitation of nose after partial rhinectomy in a patient affected with mucormycosis: a case report","author":"Jain","year":"2021","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"2024062717013111900_bib88","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jmii.2021.12.007","article-title":"COVID-19 associated mucormycosis\u2014an emerging threat","volume":"55","author":"Chao","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"2024062717013111900_bib89","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11046-021-00528-2","article-title":"Coronavirus disease (COVID-19) associated mucormycosis (CAM): case report and systematic review of literature","volume":"186","author":"Garg","year":"2021","journal-title":"Mycopathologia"},{"key":"2024062717013111900_bib90","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3389\/fpubh.2020.00382","article-title":"Transforming a general hospital to an infectious disease hospital for COVID-19 over 2 weeks","volume":"8","author":"Pandey","year":"2020","journal-title":"Front Public Health"},{"key":"2024062717013111900_bib91","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00358-18","article-title":"Molecular identification and susceptibility testing of molds isolated in a prospective surveillance of triazole resistance in Spain (FILPOP2 Study)","volume":"62","author":"Alastruey-Izquierdo","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062717013111900_bib92","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1128\/AAC.01919-15","article-title":"In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order","volume":"59","author":"Arendrup","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062717013111900_bib93","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/myc.12981","article-title":"Estimated burden of fungal infections in Sweden","volume":"62","author":"\u00d6zenci","year":"2019","journal-title":"Mycoses"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/62\/6\/myad130\/58350503\/myad130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/62\/6\/myad130\/58350503\/myad130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T20:11:17Z","timestamp":1719519077000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/doi\/10.1093\/mmy\/myad130\/7700340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,27]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myad130","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,6]]},"article-number":"myad130"}}